← All trials
NCT05614063
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 18, 2022
- Primary completion
- Apr 30, 2025
- Completion date
- Jun 30, 2025
- First posted
- Nov 14, 2022
- Last posted
- Dec 14, 2022
- Enrollment
- 360
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xenon Pharmaceuticals Inc.Lead sponsor
- Xenon Pharmaceuticals Inc.Study director
- Worldwide Clinical TrialsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.